Login to Your Account

Mixed Bag of Anti-Scarring Midstage Data Drops Renovo

By Jennifer Boggs

Tuesday, March 4, 2008
Shares of Renovo plc tumbled 51 percent after its anti-scarring product, Juvista, missed its endpoint in a Phase II trial in patients undergoing breast augmentation surgery, leading investors to worry about the product's chances for broad label approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription